AmeriFlex Group’s Recursion Pharmaceuticals RXRX Stock Holding History

AmeriFlex Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.34K	Hold	2,000	–	–	﹤0.01%	935
2026 Q1	$6.14K	Hold	2,000	–	–	﹤0.01%	802
2025 Q4	$8.18K	Buy	2,000 +1,876	+1,513%	+$9.29K	﹤0.01%	750
2025 Q3	$605	Buy	124 +62	+100%	+$326	﹤0.01%	1025
2025 Q2	$335	Sell	62 -2,000	-97%	-$9.82K	﹤0.01%	1030
2025 Q1	$10.9K	Buy	2,062 +2,000	+3,226%	+$14.6K	﹤0.01%	827
2024 Q4	$449	Buy	+62	New	+$417	﹤0.01%	1127

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AmeriFlex Group's RXRX Position: Q2 2026 in Review

AmeriFlex Group held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 2,000 shares worth $7.34K. The position accounts for ﹤0.01% of the portfolio, ranked #935.

AmeriFlex Group first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $10.9K in Q1 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

AmeriFlex Group held 2,000 shares of Recursion Pharmaceuticals worth $7.34K as of Q2 2026.
AmeriFlex Group left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of AmeriFlex Group's portfolio in Q2 2026, its #935 holding.
AmeriFlex Group first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
AmeriFlex Group's Recursion Pharmaceuticals position peaked at $10.9K in Q1 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on AmeriFlex Group's 13F filing for Q2 2026, filed 14 Aug 2026.